ID:4007 Immune-cell base for cancer therapy

Main Article Content

Van Thanh Ta Thinh Huy Tran Binh Thanh Nguyen Linh Quy Nguyen Hoai Quy Nguyen Khanh Van Tran


The development of immune cell-based approaches for treatment of cancer has been actively investigated for many years. One strategy that has been demonstrated as an effective method for cancer treatment is adoptive T cell therapy. The principle of this method is using Cytotoxic T lymphocytes (CTL), a crucial component of the adaptive immune system that aids in the control of intracellular pathogens. Effector CTL have the capacity to promote the apoptotic death of specifically targeted cells, using a combination of granule (perforin/granzyme)-and receptor (Fas/tumor necrosis factor)-mediated mechanisms. CTL recognize specific antigen on target cells using an unique T-cell receptor (TCR) when they are presented by class I major histocompatibility (MHC) molecules. In this study, we demonstrated that T lymphocytes were activated and dramatically expanded by stimulation with anti-CD3/CD28 antibodies and culture in the present of IL-2, IL-15 and IL-21 cytokines. These T cells exhibited a predominantly activated phenotype as manifested by an increase in the percentage of cells expressing CD8 and generation of various cytokines such as IL-2, INFγ and TNFa. These findings indicate that stimulation by anti- CD3/CD28 generated effector CTL in adoptive T-cell therapy for cancer.


Download data is not yet available.

Article Details

How to Cite
TA, Van Thanh et al. ID:4007 Immune-cell base for cancer therapy. Biomedical Research and Therapy, [S.l.], v. 4, n. S, p. S10, sep. 2017. ISSN 2198-4093. Available at: <>. Date accessed: 23 oct. 2017. doi:
Oral Abstracts